• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down3.39% Nasdaq Down4.12%

    Horizon Pharma plc (HZNP)

    16.25 Down 1.19(6.82%) 4:00PM EDT
    |After Hours : 16.25 Down 0.00 (0.01%) 5:04PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Horizon Pharma plc
    Connaught House
    1st Floor
    Dublin, 4
    Ireland - Map
    Phone: 353 1 772 2100
    Website: http://www.horizonpharma.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:890

    Business Summary 

    Horizon Pharma plc, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; DUEXIS and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and PENNSAID for the treatment of pain of osteoarthritis of the knees. Its products also include MIGERGOT to treat vascular headache; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus and multiple other indications; and KRYSTEXXA to treat chronic refractory gout. The company has a collaboration agreement with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Horizon Pharma plc

    Corporate Governance 
    Horizon Pharma plc’s ISS Governance QuickScore as of Jul 1, 2015 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 4; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Timothy P. Walbert , 49
    Chairman, Chief Exec. Officer and Pres
    Mr. Paul W. Hoelscher , 51
    Chief Financial Officer and Exec. VP
    Mr. Robert F. Carey , 57
    Chief Bus. Officer and Exec. VP
    Mr. George P. Hampton , 46
    Exec. VP of Global Orphan Bus. Unit, Primary Care and International Operations
    Mr. Barry J. Moze , 62
    Chief Operating Officer and Exec. VP
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders